Key result
Unstable angina and acute MI are linked to ~120% higher basal platelet cGMP versus controls.
Why the study?
The study aimed to investigate if the platelet nitric oxide-cyclic GMP pathway regulating platelet aggregation is altered in patients with unstable angina and acute myocardial infarction.
Are platelet cGMP levels altered in patients with unstable angina and acute myocardial infarction compared to controls?
Case-Control (n=46)
Are platelet cGMP levels altered in patients with unstable angina and acute myocardial infarction compared to controls?
p-value: p=<0.001
Basal platelet cGMP is significantly elevated in unstable angina and acute myocardial infarction, indicating altered platelet nitric oxide-cGMP pathway dynamics in acute coronary syndromes.
Elevated platelet cGMP in ACS may indicate NO-cGMP pathway dysregulation; leaves open causal role and therapeutic relevance.
BACKGROUND: Several studies showed that there is a state of platelet hyperactivaction in patients with coronary syndrome: the aim of this study is to investigate if the platelet nitric oxide-cyclicGMP (NO-cGMP) pathway, that regulates platelet aggregation is altered in patients with unstable angina (UA) and acute myocardial infarction (AMI). METHODS AND RESULTS: Population included 11 patients with UA, 12 patients with AMI and 23 controls. Platelet cGMP was measured by a radioimmunoassay kit, under basal conditions and after stimulation with sodium nitroprusside (SNP), which maximally stimulates soluble guanylate cyclase (sGC), used as an indirect measurement of active sGC. Basal platelet cGMP values were significantly (P<0.001) higher in patients with UA and AMI than in controls (UA, 1089 +/- 412 pmol/10(10) platelets; AMI, 1071 +/- 507 pmol/10(10) platelets; controls, 492 +/- 201 pmol/10(10) platelets). The final cGMP level reached after SNP stimulation was significantly more elevated in UA, compared with both AMI (P<0.05) and controls (P<0.02) (UA, 4428 +/- 2723 pmol/10(10) platelets; AMI, 2728 +/- 655 pmol/10(10) platelets; controls, 2772 +/- 1031 pmol/10(10) platelets); on the contrary no significant difference between AMI and controls was observed. CONCLUSIONS: Basal platelet cGMP is significantly higher in both UA and AMI groups. This observation suggests that: (1) platelet-derived NO synthesis may be enhanced inUA and AMI, due to increase of intraplatelet calcium level and of platelet cNOS activation; (2) platelets from UA and AMI patients are continuously stimulated by the high-level NO production due to increased iNOS expression. As far as SNP-dependent cGMP production is concerned, UA and AMI behave as two separate conditions. SNP-stimulated activity in UA is higher than in controls, while a loss of functional sGC is observed in AMI.
No takes yet. Share an insight, caveat, or question.
Pistono et al. (2002) conducted a case-control in Unstable angina and acute myocardial infarction (n=46). Unstable angina and acute myocardial infarction vs. Controls was evaluated on Basal platelet cGMP values (p=<0.001). Unstable angina and acute myocardial infarction were associated with significantly higher basal platelet cGMP values compared to controls (1089 and 1071 vs 492 pmol/10^10 platelets; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: